Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

Yahya BUYUKASIK

首页> 外文期刊>International Journal of Hematology and Oncology >Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

【24h】

Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

机译：伊马替尼治疗失败后使用第二代酪氨酸激酶抑制剂对慢性粒细胞白血病进行二线治疗

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Hematology and Oncology》 |2016年第4期|共页
作者
Yahya BUYUKASIK;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
入库时间 2022-08-18 09:09:24

相似文献

外文文献
中文文献
专利

1. BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution [J] . Ribeiro Beatriz Felicio, Vergilio Bruna Rocha, Martins Miranda Eliana Cristina, Acta Haematologica . 2015,第4期

机译：3个月和6个月的BCR-ABL1转录水平更好地确定在伊马替尼治疗失败后对第二线第二代酪氨酸激酶抑制剂反应不良的慢性粒细胞白血病患者：一家机构的报告
2. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter? [J] . BranfordS., MeloJ.V., HughesT.P. Blood: The Journal of the American Society of Hematology . 2009,第27期

机译：为伊马替尼治疗失败后的慢性粒细胞白血病患者选择最佳的二线酪氨酸激酶抑制剂治疗：BCR-ABL突变状态真的重要吗？
3. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. [J] . Jabbour E, Jones D, Kantarjian HM, Blood: The Journal of the American Society of Hematology . 2009,第10期

机译：伊马替尼治疗失败后，使用第二代酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者的长期预后可通过BCR-ABL激酶域突变的体外敏感性来预测。
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Clinical Trials and Observations: Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations [O] . Elias Jabbour, Daniel Jones, Hagop M. Kantarjian, -1

机译：临床试验和观察：伊马替尼治疗失败后用第二代酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者的长期预后可通过BCR-ABL激酶域突变的体外敏感性来预测
7. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? [O] . Branford S., Vaz de Melo J., Hughes T. 2009

机译：在伊马替尼治疗失败后为慢性粒细胞白血病患者选择最佳的二线酪氨酸激酶抑制剂治疗：BCR-aBL突变状态真的重要吗？

Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

著录项

相似文献

相关主题

期刊订阅